Results 181 to 190 of about 107,650 (261)

Postnatal determinants of testicular germ cell tumor by histological subtypes: The EPSAM1 and EPSAM2 studies. [PDF]

open access: yesInt J Cancer
Cioffi M   +10 more
europepmc   +1 more source

Interventional oncology in children: Where are we now?

open access: yesJournal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel   +1 more
wiley   +1 more source

Oncology Inpatient Resuscitation Planning and Long‐Term “Rapid Response Call” Outcomes

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
Optimal end‐of‐life care involves a patient‐centered approach. The dual audits presented in this study show that a proportion of oncology patients receiving palliative‐intent cancer treatment continue to be managed in hospital without a resuscitation plan and may undergo care escalation to a “rapid response” intervention despite poor prognosis ...
Dhanashree Tikhe   +3 more
wiley   +1 more source

Testicular histopathology and its association with germ cell numbers, serum concentrations of reproductive hormones, and semen quality

open access: yesAndrology, EarlyView.
Abstract Background It is well‐established that spermatogenesis, semen quality, and reproductive hormones are interlinked. It is, however, less well‐described how various specific testicular histopathologies are linked to reproductive hormones and semen quality.
Gülizar Saritas   +6 more
wiley   +1 more source

BRD9 inhibition as potential treatment option for testicular germ cell tumors

open access: yesAndrology, EarlyView.
Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy